Brawn Biotech Limited , a pharmaceutical company, has announced its financial results for the second quarter ended September 30, 2025. The company reported a net loss of Rs. 7.44 lacs for the quarter, with revenue from operations standing at Rs. 797.00 lacs.

Key Financial Highlights

Financial Performance Analysis

Brawn Biotech's revenue from operations showed a significant improvement compared to both the previous quarter and the same quarter last year. However, despite the increase in revenue, the company reported a net loss for the quarter.

Operational Highlights

• The Board of Directors approved the unaudited financial results in their meeting held on November 14, 2025.
• The company's total expenses for the quarter stood at Rs. 798.98 lacs, showing an increase from the previous quarter.
• Other income for the quarter was Rs. 9.12 lacs, remaining relatively stable compared to the previous quarter.

Balance Sheet Overview

As of September 30, 2025, Brawn Biotech reported:

• Total assets of Rs. 2,215.67 lacs
• Total equity of Rs. 370.52 lacs
• Current liabilities of Rs. 1,885.15 lacs

Auditor's Review

Rajiv Udai & Associates, Chartered Accountants, conducted a limited review of the financial results. They stated that nothing has come to their attention that causes them to believe that the financial results do not present a true and fair view in accordance with applicable accounting standards and other recognized accounting practices and policies.

Investors and stakeholders are advised to consider these results in the context of overall market conditions and the pharmaceutical industry's performance.

Brawn Biotech Limited , a pharmaceutical company, held its 40th Annual General Meeting (AGM) on September 30, 2025, where shareholders approved several important resolutions. The meeting, conducted through video conferencing, saw active participation from shareholders and key company officials.

Key Resolutions Approved

Manager Re-appointment

Shareholders approved the re-appointment of Mr. Amit Kumar as the Manager (Key Managerial Personnel) of the company for an additional five-year term, from February 12, 2026, to February 11, 2031. Kumar, who holds a Post Graduate Diploma in Business Administration, brings over a decade of experience in operations and sales within the pharmaceutical industry to his role.

Corporate Document Update

In alignment with current regulations, shareholders approved the adoption of a new Memorandum of Association (MoA) in compliance with the Companies Act, 2013. This special resolution ensures that Brawn Biotech's corporate documents are up-to-date with the latest legal requirements. The company clarified that while the MoA was updated, there were no changes to the main objects of the company.

Financial Statement Adoption and Director Re-appointment

Other resolutions passed at the AGM included:

• Adoption of the audited financial statements for the year ended March 31, 2025
• Re-appointment of Mrs. Brij Bala Gupta, who retired by rotation and offered herself for re-appointment

Voting Results

The company reported strong shareholder support for all resolutions:

Meeting Details

The AGM, which began at 11:00 AM, concluded at 11:13 AM, with e-voting remaining open for an additional 30 minutes. Mr. Brij Raj Gupta presided over the meeting as Chairman.

Brawn Biotech's commitment to transparency and compliance was evident in their prompt disclosure of the AGM proceedings and voting results to the Bombay Stock Exchange, in line with regulatory requirements.